Cargando…

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis

Immune mechanisms may be important in the pathogenesis of Alzheimer’s disease (AD). Yet, studies comparing cerebrospinal fluid (CSF) and plasma immune marker levels of healthy and demented individuals have yielded conflicting results. We analyzed CSF from 101 members of the parental history-positive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer, Pierre-François, Savard, Melissa, Poirier, Judes, Labonté, Anne, Rosa-Neto, Pedro, Weitz, Tara M., Town, Terrence, Breitner, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929310/ https://www.ncbi.nlm.nih.gov/pubmed/29660934 http://dx.doi.org/10.3233/JAD-170887

Ejemplares similares

No apparent effect of naproxen on CSF markers of innate immune activation
por: Meyer, Pierre‐François, et al.
Publicado: (2019)

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
por: Meyer, Pierre-François, et al.
Publicado: (2019)

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer’s Disease
por: Tuwaig, Miranda, et al.
Publicado: (2017)

Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease
por: Picard, Cynthia, et al.
Publicado: (2021)

Microglia in Alzheimer's Disease: It's All About Context
por: Weitz, Tara M., et al.
Publicado: (2012)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study
por: Picard, Cynthia, et al.
Publicado: (2019)

Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum
por: Nilsson, Nathalie I. V., et al.
Publicado: (2021)

Could Lipoprotein Lipase Play a Role in Alzheimer's Disease?
por: Blain, Jean-Francois, et al.
Publicado: (2004)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease
por: Vogel, Jacob W, et al.
Publicado: (2018)

Transmission of ALS pathogenesis by the cerebrospinal fluid
por: Mishra, Pooja Shree, et al.
Publicado: (2020)

Multi-Shell Hybrid Diffusion Imaging (HYDI) at 7 Tesla in TgF344-AD Transgenic Alzheimer Rats
por: Daianu, Madelaine, et al.
Publicado: (2015)

Importance of extracellular vesicle secretion at the blood–cerebrospinal fluid interface in the pathogenesis of Alzheimer’s disease
por: Vandendriessche, Charysse, et al.
Publicado: (2021)

Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer’s Disease
por: Konishi, Kyoko, et al.
Publicado: (2018)

Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease
por: Kramberger, Milica Gregoric, et al.
Publicado: (2012)

Odor identification as a biomarker of preclinical AD in older adults at risk
por: Lafaille-Magnan, Marie-Elyse, et al.
Publicado: (2017)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study
por: Henderson, Samuel T, et al.
Publicado: (2011)

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
por: Dumurgier, Julien, et al.
Publicado: (2013)

Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease
por: Brosseron, Frederic, et al.
Publicado: (2018)

Cerebral Microbleeds, Cerebrospinal Fluid, and Neuroimaging Markers in Clinical Subtypes of Alzheimer's Disease
por: Ikeda, Masaki, et al.
Publicado: (2021)

Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease
por: Silverberg, Gerald, et al.
Publicado: (2006)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

A cerebrospinal fluid biosignature for the diagnosis of Alzheimer’s disease
por: Barichello, Tatiana, et al.
Publicado: (2019)

Putative autoantibodies in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lim, Bryant, et al.
Publicado: (2019)

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease
por: Do, Khanh V., et al.
Publicado: (2022)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Tau protein as a possible marker of cerebrospinal fluid leakage in cerebrospinal fluid rhinorrhoea: A pilot study
por: Oudart, Jean-Baptiste, et al.
Publicado: (2017)

Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease
por: Jensen, Camilla Steen, et al.
Publicado: (2017)

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2021)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
por: Babić, Mirjana, et al.
Publicado: (2014)

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
por: Henjum, Kristi, et al.
Publicado: (2016)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aimmb803ovtc9e173odirfo9ij